Medivation Inc (NASDAQ:MDVN) price target upped to $81.00, reported earlier today by Barclays PLC
- Updated: September 17, 2016
Only yesterday Medivation Inc (NASDAQ:MDVN) traded 0.22% lower at $80.39. The company’s 50-day average is $73.40 and its two hundred day average is $58.80. The last stock price is up 37.54% from the 200-day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. 5,722,621 shares of MDVN were exchanged, up from ann average volume of 3,969,200.
Stating a possible upside of 0.01%, Barclays PLC raised the price target of Medivation Inc (NASDAQ:MDVN) to $81
See Graphic Below:
A total of 17 brokers have released a ratings update on the company. Five firms rate the company a strong buy, six analysts rate the stock a buy, 10 firms rate the company a hold, 0 rate the stock to underperform, and finally 0 firmsrate the company as sell with a one year target stock price of $62.35
Medivation Inc has a 52 week low of $26.41 and a one-year high of $81.15 . Medivation Inc’s total market value is currently $0.0.
More About Medivation Inc (NASDAQ:MDVN)
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, and pathway which it refers to as MDV4463.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.